Cargando…
Defining myocardial fibrosis in haemodialysis patients with non-contrast cardiac magnetic resonance
BACKGROUND: Extent of myocardial fibrosis (MF) determined using late gadolinium enhanced (LGE) predicts outcomes, but gadolinium is contraindicated in advanced renal disease. We assessed the ability of native T1-mapping to identify and quantify MF in aortic stenosis patients (AS) as a model for use...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044074/ https://www.ncbi.nlm.nih.gov/pubmed/30005636 http://dx.doi.org/10.1186/s12872-018-0885-2 |
_version_ | 1783339408916742144 |
---|---|
author | Graham-Brown, M. P. Singh, A. S. Gulsin, G. S. Levelt, E. Arnold, J. A. Stensel, D. J. Burton, J. O. McCann, G. P. |
author_facet | Graham-Brown, M. P. Singh, A. S. Gulsin, G. S. Levelt, E. Arnold, J. A. Stensel, D. J. Burton, J. O. McCann, G. P. |
author_sort | Graham-Brown, M. P. |
collection | PubMed |
description | BACKGROUND: Extent of myocardial fibrosis (MF) determined using late gadolinium enhanced (LGE) predicts outcomes, but gadolinium is contraindicated in advanced renal disease. We assessed the ability of native T1-mapping to identify and quantify MF in aortic stenosis patients (AS) as a model for use in haemodialysis patients. METHODS: We compared the ability to identify areas of replacement-MF using native T1-mapping to LGE in 25 AS patients at 3 T. We assessed agreement between extent of MF defined by LGE full-width-half-maximum (FWHM) and the LGE 3-standard-deviations (3SD) in AS patients and nine T1 thresholding-techniques, with thresholds set 2-to-9 standard-deviations above normal-range (1083 ± 33 ms). A further technique was tested that set an individual T1-threshold for each patient (T11SD). The technique that agreed most strongly with FWHM or 3SD in AS patients was used to compare extent of MF between AS (n = 25) and haemodialysis patients (n = 25). RESULTS: Twenty-six areas of enhancement were identified on LGE images, with 25 corresponding areas of discretely increased native T1 signal identified on T1 maps. Global T1 was higher in haemodialysis than AS patients (1279 ms ± 5.8 vs 1143 ms ± 12.49, P < 0.01). No signal-threshold technique derived from standard-deviations above normal-range associated with FWHM or 3SD. T11SD correlated with FWHM in AS patients (r = 0.55) with moderate agreement (ICC = 0.64), (but not with 3SD). Extent of MF defined by T11SD was higher in haemodialysis vs AS patients (21.92% ± 1 vs 18.24% ± 1.4, P = 0.038), as was T1 in regions-of-interest defined as scar (1390 ± 8.7 vs 1276 ms ± 20.5, P < 0.01). There was no difference in the relative difference between remote myocardium and regions defined as scar, between groups (111.4 ms ± 7.6 vs 133.2 ms ± 17.5, P = 0.26). CONCLUSIONS: Areas of MF are identifiable on native T1 maps, but absolute thresholds to define extent of MF could not be determined. Histological studies are needed to assess the ability of native-T1 signal-thresholding techniques to define extent of MF in haemodialysis patients. Data is taken from the PRIMID-AS (NCT01658345) and CYCLE-HD studies (ISRCTN11299707). |
format | Online Article Text |
id | pubmed-6044074 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60440742018-07-16 Defining myocardial fibrosis in haemodialysis patients with non-contrast cardiac magnetic resonance Graham-Brown, M. P. Singh, A. S. Gulsin, G. S. Levelt, E. Arnold, J. A. Stensel, D. J. Burton, J. O. McCann, G. P. BMC Cardiovasc Disord Research Article BACKGROUND: Extent of myocardial fibrosis (MF) determined using late gadolinium enhanced (LGE) predicts outcomes, but gadolinium is contraindicated in advanced renal disease. We assessed the ability of native T1-mapping to identify and quantify MF in aortic stenosis patients (AS) as a model for use in haemodialysis patients. METHODS: We compared the ability to identify areas of replacement-MF using native T1-mapping to LGE in 25 AS patients at 3 T. We assessed agreement between extent of MF defined by LGE full-width-half-maximum (FWHM) and the LGE 3-standard-deviations (3SD) in AS patients and nine T1 thresholding-techniques, with thresholds set 2-to-9 standard-deviations above normal-range (1083 ± 33 ms). A further technique was tested that set an individual T1-threshold for each patient (T11SD). The technique that agreed most strongly with FWHM or 3SD in AS patients was used to compare extent of MF between AS (n = 25) and haemodialysis patients (n = 25). RESULTS: Twenty-six areas of enhancement were identified on LGE images, with 25 corresponding areas of discretely increased native T1 signal identified on T1 maps. Global T1 was higher in haemodialysis than AS patients (1279 ms ± 5.8 vs 1143 ms ± 12.49, P < 0.01). No signal-threshold technique derived from standard-deviations above normal-range associated with FWHM or 3SD. T11SD correlated with FWHM in AS patients (r = 0.55) with moderate agreement (ICC = 0.64), (but not with 3SD). Extent of MF defined by T11SD was higher in haemodialysis vs AS patients (21.92% ± 1 vs 18.24% ± 1.4, P = 0.038), as was T1 in regions-of-interest defined as scar (1390 ± 8.7 vs 1276 ms ± 20.5, P < 0.01). There was no difference in the relative difference between remote myocardium and regions defined as scar, between groups (111.4 ms ± 7.6 vs 133.2 ms ± 17.5, P = 0.26). CONCLUSIONS: Areas of MF are identifiable on native T1 maps, but absolute thresholds to define extent of MF could not be determined. Histological studies are needed to assess the ability of native-T1 signal-thresholding techniques to define extent of MF in haemodialysis patients. Data is taken from the PRIMID-AS (NCT01658345) and CYCLE-HD studies (ISRCTN11299707). BioMed Central 2018-07-13 /pmc/articles/PMC6044074/ /pubmed/30005636 http://dx.doi.org/10.1186/s12872-018-0885-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Graham-Brown, M. P. Singh, A. S. Gulsin, G. S. Levelt, E. Arnold, J. A. Stensel, D. J. Burton, J. O. McCann, G. P. Defining myocardial fibrosis in haemodialysis patients with non-contrast cardiac magnetic resonance |
title | Defining myocardial fibrosis in haemodialysis patients with non-contrast cardiac magnetic resonance |
title_full | Defining myocardial fibrosis in haemodialysis patients with non-contrast cardiac magnetic resonance |
title_fullStr | Defining myocardial fibrosis in haemodialysis patients with non-contrast cardiac magnetic resonance |
title_full_unstemmed | Defining myocardial fibrosis in haemodialysis patients with non-contrast cardiac magnetic resonance |
title_short | Defining myocardial fibrosis in haemodialysis patients with non-contrast cardiac magnetic resonance |
title_sort | defining myocardial fibrosis in haemodialysis patients with non-contrast cardiac magnetic resonance |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044074/ https://www.ncbi.nlm.nih.gov/pubmed/30005636 http://dx.doi.org/10.1186/s12872-018-0885-2 |
work_keys_str_mv | AT grahambrownmp definingmyocardialfibrosisinhaemodialysispatientswithnoncontrastcardiacmagneticresonance AT singhas definingmyocardialfibrosisinhaemodialysispatientswithnoncontrastcardiacmagneticresonance AT gulsings definingmyocardialfibrosisinhaemodialysispatientswithnoncontrastcardiacmagneticresonance AT levelte definingmyocardialfibrosisinhaemodialysispatientswithnoncontrastcardiacmagneticresonance AT arnoldja definingmyocardialfibrosisinhaemodialysispatientswithnoncontrastcardiacmagneticresonance AT stenseldj definingmyocardialfibrosisinhaemodialysispatientswithnoncontrastcardiacmagneticresonance AT burtonjo definingmyocardialfibrosisinhaemodialysispatientswithnoncontrastcardiacmagneticresonance AT mccanngp definingmyocardialfibrosisinhaemodialysispatientswithnoncontrastcardiacmagneticresonance |